top of page
Bioelectronic Medicine · Cardiovascular Health

Reimagining the Future of Cardiovascular Health.

Afferent Medical Solutions is developing a novel algorithm of non-invasive, device-based neuromodulation for the treatment of hypertension and other cardiovascular diseases.

insitu p3 face swap i.jpg

Conceptual prototype mock-up | Technology under development

FEATURED IN THE MEDIA
The-Standard-logo.png
ASDASDQ.jpg
The-Herald-logo-2.jpg
Bioelectronic Medicine · Hypertension

-12.7 mmHg*

A signal in participants with higher baseline blood pressure.

* Treatment difference versus sham in the prespecified subgroup with baseline daytime systolic blood pressure ≥160 mmHg.

OUR FOCUS

Neuromodulation for cardiovascular diseases

Device-based approaches developed from decades of basic science research

OUR APPROACH

Non-invasive and designed for home use

AffeX technology is a device designed for a guided treatment session.

OUR WORK

Research, technology and patient support

Clinical evidence and connected-care tools are being developed together.

WHO WE ARE 

Improving Human Health Through Research and Technology.

Afferent is a bioelectronic medicine company founded on decades of academic neuroscience research. The company was established to develop and commercialise advances in device-based neuromodulation for diseases of the circulatory system and other therapeutic areas where existing pharmacological treatments remain inadequate.

​

Afferent is a UK-based medical technology company bringing together scientific, clinical and engineering expertise to develop and commercialise innovative neuromodulation therapies.

​

More about Afferent ↗

OUR TECHNOLOGY

One Connected Approach, from Device to Care Team.

AffeX and AffeX+ are being developed to bring together the treatment device, patient support and clinician oversight.

insitu p4(1).jpg

THE DEVICE

AffeX

AffeX technology delivers a programmed session of transcutaneous auricular stimulation.

​

Explore the device â†—

qweasdxza.png

CONNECTED CARE

AffeX+

Digital platform connects patients and healthcare professionals with treatment information and remote support.

​

Explore AffeX+ â†—

Untitledaweqwe.png

PATIENT CARE

Designed around daily use

The treatment is intended to fit into a simple home routine, with a typical session lasting 30 minutes during treatment course.

​

See how it works â†— 

Conceptual prototype mock-up 

Untitledweqweasd.png

Conceptual prototype mock-up | Technology under development 

DIGITAL SUPPORT 

Turning Daily Readings Into a Clearer Picture.

AffeX+ is an integrated digital health platform currently under development, being designed to connect patients and healthcare professionals within a unified treatment management ecosystem. The platform will combine remote patient monitoring, treatment adherence tracking and clinical decision support to facilitate personalised therapy and continuous clinical oversight.

​

Exlore the digital platform ↗

afferent_ai_precisely_aligned_4k.png
PERSONALISED 

Identifying Responders with AI 

Afferent is developing an AI-powered predictive model to identify patients most likely to benefit from tanX therapy. By integrating cardiovascular, physiological and clinical data, the system predicts individual treatment responsiveness and anticipated therapeutic efficacy, supporting a personalised approach to hypertension management.

​​

“Our non-invasive device-based technology is truly a game changer that has the potential to improve the health of millions of hypertensive patients.”

Prof. K. Michael Spyer · Chair at Afferent · Ex-Chair NHS London

BASED IN THE UK 

Bringing Research and Technology Together

Afferent Medical Solutions is a UK-based, privately funded bioelectronics medicine company.  

​

Meet the team ↗

Interested in the science, technology or partnering with Afferent?

bottom of page